Cell and Gene Therapy Market Scenario | DelveInsight
The Evolved Gene Therapy for Hemophilia
car-t-cell-therapy-market-competitive-landscape-key-players
CAR-T Cell Therapy aka Miraculous Tec...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative potential as a new type...

Avrobios-Gene-Therapy-for-Cystinosis
Avrobio’s Gene Therapy for Cystinosis...

Cystinosis is a genetic condition that causes the buildup of the amino acid "cystine" in the cells of the b...

Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person aff...

companies-in-gene-therapy-for-dermatology
Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology Segment

Advances in genetics research have sparked a surge in interest in gene therapy in dermatology in recent years. Dermatology treatment options have expanded beyond topical drugs to include oral medi...


gene-therapies-in-dermatology
Development of Gene Therapies in Dermatology

What is Gene Therapy and Is the Skin Suitable for Gene Therapy? Since its first discovery, conceptualization in 1972, and successful application in 1990 by W. French Anderson, gene therapy has ...


pharma-biotech-news-updates-for-pfizer-kytopen-eli-lilly-vensana-reify-health
Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reif...

Pfizer tightens DMD patient criteria after serious adverse events in phase 3 gene therapy trial Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to partake in phase...


Intratumoral Cancer Therapy Market
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer

Cancer is a leading cause of global death, accounting for nearly 10 million deaths in 2020.  However, over the past years, the treatment paradigm of Cancer has transformed with several therap...


recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus
BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M b...

BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron ther...


pharma-happenings-for-arrowhead-sartorius-sirnaomics-agc-biologics
Arrowhead’s ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics&#...

Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial  Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of AR...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...